Friday, October 9, 2020

Cadila: Rebound in domestic formulations to add to US sales, drive earnings

In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages

from Today's Paper https://ift.tt/3jCSAQV
via

No comments:

Post a Comment

If you have any doubts please let me know!

India's low score on GVC a starting point for recovery from pandemic: AIIB

India rated 7.4 percentage points below the average global value chain participation rate for emerging economies from Today's Paper ht...